Related Experiment Video
Updated: Sep 27, 2026
Rapid In Vitro Cytotoxicity Evaluation of Jurkat Expressing Chimeric Antigen Receptor using Fluorescent Imaging
Published on: October 27, 2023
The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein
Hiromitsu Jinno1, Masakazu Ueda, Soji Ozawa
1Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan.
Background:
Conventional targeted therapy with foreign proteins is highly immunogenic. In this study, we developed targeted therapy composed of human endogenous proteins and evaluated its efficacy in vitro.
Materials And Methods:
Human epidermal growth factor (EGF) was chemically linked to human eosinophil cationic protein (ECP). The cytotoxicity of the EGF-ECP conjugate was evaluated by MTT assay.
Results:
The conjugate showed dose-dependent cytotoxicity on EGF receptor (EGFR)-overexpressing BT-20 cells with an IC50 of 1.5 x 10(-7) M, whereas the IC50 of ECP alone was almost 10(-4) M. The conjugate had no detectable cytotoxicity against EGF receptor-deficient H69 cells. Excess EGF protected BT-20 cells from the cytotoxicity of the conjugate. Comparing the cytotoxicity and the level of EGFR expression, the cytotoxicity of the conjugate was positively correlated with the level of EGFR expression of each cell line.
Conclusion:
Conjugates composed solely of human proteins might be useful with less immunogenicity and less toxicity than the conventional immunotoxins for targeted therapy.
Insights
This study developed targeted therapy using human proteins, linking epidermal growth factor (EGF) to eosinophil cationic protein (ECP). The novel EGF-ECP conjugate demonstrated targeted cell killing with reduced immunogenicity and toxicity.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Development
Background:
- Conventional targeted therapies often use foreign proteins, leading to high immunogenicity.
- Developing targeted therapies with endogenous proteins can mitigate immune responses.
Purpose of the Study:
- To create and evaluate a targeted therapy using human endogenous proteins.
- To assess the efficacy and specificity of a novel human protein conjugate for targeted therapy.
Main Methods:
- Human epidermal growth factor (EGF) was conjugated to human eosinophil cationic protein (ECP).
- Cytotoxicity of the EGF-ECP conjugate was assessed using MTT assays on cell lines with varying EGF receptor (EGFR) expression.
Main Results:
- The EGF-ECP conjugate exhibited dose-dependent cytotoxicity against EGFR-overexpressing BT-20 cells (IC50 = 1.5 x 10(-7) M).
- The conjugate showed minimal cytotoxicity against EGFR-deficient H69 cells, indicating specificity.
- Cytotoxicity correlated positively with EGFR expression levels, and excess EGF neutralized the conjugate's effect.
Conclusions:
- Conjugates made entirely of human proteins offer a promising alternative to conventional immunotoxins.
- This approach may reduce immunogenicity and toxicity in targeted therapy applications.
